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doi:10.1016/j.ejvs.2008.03.006Abstract Background: Four randomised controlled trials of screening older men for abdomi-
nal aortic aneurysms (AAA) have been completed. A meta-analysis was performed to examine
the pooled effects of screening on both mid- and long-term AAA-related and total mortality,
and operations for AAA.
Methods: Pooled mid-term (3½e5 years) and long term (7e15 years) effects were calculated
as odds-ratios (ORs) with 95% confidence intervals in fixed effect models. Long-term data from
the West Australian trial were limited to all-caurse deaths. Heterogeneity between the studies
was assessed by the c2-test. In cases of heterogeneity, random effect models were used.
Results: The pooled mid-term analysis showed the offer of screening caused a significant re-
duction in AAA related mortality (ORZ 0.56, 95% C.I. 0.44,0.72), and emergency operations
(ORZ 0.55, 95% C.I.: 0.39; 0.76), while the number of elective operations increased signifi-
cantly (ORZ 3.27, 95% C.I.: 2.14; 5.00). Overall mortality was reduced, but not significantly
(ORZ 0.94, 95% C.I.: 0.86; 1.02). The long-term results also showed a significant reduction
in AAA-related mortality (ORZ 0.47, 95% C.I.: 0.25; 0.90), overall mortality (ORZ 0.94, 95%
C.I.: 0.92; 0.97) and emergency operations (ORZ 0.48, 95% C.I.: 0.28; 0.83), while the number
of elective operations increased significantly (ORZ 2.81, 95% C.I.: 2.40; 3.30).
Conclusion: Population screening for AAA reduces AAA-related and overall mortality, however
local differences may exits which could influence cost effectiveness of screening.
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168 J.S. Lindholt, P. NormanIntroduction AnalysesIn spite of an increasing elective surgery for asymptomatic
abdominal aortic aneurysm (AAA), the sex- and age-standard-
ized mortality from ruptured AAA continues to increase.1,2
The overall mortality of ruptured AAA is about 80e90%1 com-
pared to a 30 day postoperative mortality of 3.3% after elective
AAA repair in Denmark in 2006 (www.karbase.dk).
The presence of an asymptomatic phase with the
opportunity of a relatively low risk treatment compared
to the symptomatic phase raised the question of whether
screening for AAA would be effective. If seriously consid-
ered, all the criteria for screening formulated by WHO and
the Council of Europe would need to be fulfilled.1
Firstly, ultrasound scanning is a valid, suitable and
acceptable method of screening. It is fast and safe with
an estimated sensitivity and specificity of 98 and 99%,
respectively.3 Attendance rates of 53e79% have been con-
sistently achieved, and about 95% of individuals with small
AAAs attends surveillance programs.1,2
Secondly, the indications for treatment of asymptomatic
AAA are clear. The diameter of an AAA remains the most
useful risk factor for rupture, and based upon two high
quality randomised controlled trials,4,5 the threshold for
elective surgery is a diameter of 55 mm or more. For screen-
ing to be effective, the treatment must be acceptable to
patients. Those surviving surgery have the same quality of
life as the matched background population; only 2e5%
of the patients refuse surgery, although contraindications
to surgery may be present in 15% of cases. As 85e90% of
screen-detected cases are initially too small to warrant sur-
gery, they are kept under surveillance, and such surveil-
lance reduces quality of life.6 However, these issues seem
minor, if the reduction in mortality (at acceptable cost) is
substantial.1 The aims of this study were to examine the up-
dated pooled mid- and long-term effects of screening on
AAA-related and total mortality, and operations.
Search Strategy
Medline was searched with the words ‘‘Screening AND aortic
aneurysms’’ with limitation to randomised controlled trials
reported in English. 72 papers were retrieved. Relevant data
from 4 trials were identified in 9 papers: The Chichester study
(UK) with reports after 5,7 10 and 158 years of follow up, the
Multicentre Aneurysm Screening Study e MASS (UK) with
reports after 49 and 7 years,10 the West Australian Aneurysm
Screening Study (AUS)11 with results after 3.6 years, and the
Viborg Study (DK) with reports of results after 5,12 7 (AAA-re-
lated deaths)13 and10years (all deaths andAAA operations).14Table 1 Characteristics of the four randomised screening trials
Viborg Study Western Austral
Age (y) 64e73 65e83
Participants (No) 12 639 38 704
Max. Follow-up (y) 9.6 3.6
Attenders (%) 77 63
AAA-Prevalence 4.0% 7.2%Pooled mid-term effects were analysed at 3e5 years, and
long-term effects at 7e15 years, of follow up. Due to lack
of long-term results from the West Australian trial, data
from this trial were not used in the long-term analysis, with
the exception of all-cause mortality where data were
available after eleven years of follow up.
The analyses were performed using the intention to
treat principle with calculation of pooled odds-ratios
(ORs) and 95% confidence intervals (CI) in fixed effect
models. Heterogeneity between the studies was assessed
by the c2-test. In such cases, random effect models were
used. Reviewer Manager 4.2 was used as software.
Description of the Studies
All four trials described the method of randomisation.
None were blinded. The participants were mainly men
aged 64e83 years. The Chichester study also included 65e
80 year old women.7 These were excluded from the meta-
analysis in order to maximise study homogeneity. The age
groups varied between the studies; 64e73 years in Viborg,
65e74 years in MASS, 65e80 years in Chichester, and 65e
83 years in the Western Australian study. The participants
were identified by various methods. In the British studies
subjects were identified by patient registers of General
Practitioners and Family Health Service lists. In the Aus-
tralian Study men were found from the electoral roll. In
Denmark, non-selective digitalised personal identification
was used. All studies used computerised randomisation
with the participants (1:1) for being offered screening or
control status. Three of the studies established screening
sessions outside hospital by a mobile team, frequently at
General Practitioners. In the Viborg Study the screening
sessions were performed in the County hospitals by a mo-
bile screening team. All studies used abdominal ultraso-
nography for screening, and defined an AAA as an
abdominal aorta of 3 cm or more in maximal diameter.
The indication for surgery varied between the studies. In
the British studies surgery was indicated if AAA-related
symptoms were present, if the annual AAA growth rate
was 1 cm or more, or if the maximal aortic diameter ex-
ceeded 5.5 cm (MASS) or 6 cm (Chichester study). In the
Viborg study, surgery was considered if AAA-related symp-
toms were present or if the maximal aortic diameter ex-
ceeded 5 to 5.5 cm. In the Western Australian Study, the
indications for surgery were left to the individual sur-
geons. Similarly, the intervals between surveillance scans
varied between the studies.for abdominal aortic aneurysms
ia MASS Chichester, Men Combined
65e74 65e80 e
67 800 6040 125 576
7 15 e
80 73 74
4.9% 7.7% 5.5%
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The number of participants, age groups, attendance and
prevalence of AAA are summarised in Table 1. The trials in-
cluded a total of 125,576 men. Attendance rate ranged
from 70% in Western Australia to 80% in the MASS trial.Figure 1 Meta-analysis of the mid-term effects of screening 64e8
erations for AAA.The prevalence of AAA ranged from 4.0% in the Viborg Study
to 7.7% in Chichester. The analyses of the mid-term results
showed that screening caused a significant reduction in
AAA-related mortality (ORZ 0.56, 95% C.I.: 0.44; 0.72,
Fig. 1). However, the inclusion of men above 80 must be
questioned, since many may not be offered elective surgery3 year old men: AAA-related mortality, total mortality and op-
Figure 2 Meta-analysis of the long-term effects of screening 64e83 year old: AAA-related mortality, total mortality and opera-
tions for AAA.
170 J.S. Lindholt, P. Normanfor AAA. If these are excluded from the meta-analysis,
screening significantly reduced AAA-related mortality
(ORZ 0.51, 95% C.I.: 0.40; 0.67). In addition, there was
a significant reduction in overall mortality (ORZ 0.93,
95% C.I.: 0.90; 0.96), however, heterogeneity between
the studies was present and statistical significance was
lost in a random effect model (ORZ 0.94, 95% C.I.: 0.86;1.02). A significantly higher number of planned operations
(ORZ 3.27, 95% C.I.: 2.14; 5.00), and significantly fewer
emergency operations were observed (ORZ 0.55, 95%
C.I.: 0.39; 0.76, Fig. 1).
The analyses of the long-term results showed the offer
of screening caused a significant reduction in AAA-related
mortality (ORZ 0.47, 95% C.I.: 0.25; 0.90, Fig. 2). A
Screening for AAA Reduces Overall Mortality 171significant reduction of overall mortality was also noticed
(ORZ 0.94, 95% C.I.: 0.92; 0.97), without significant het-
erogeneity between the studies. If a random effect model
had been used, the reduction would still be statistically sig-
nificant (ORZ 0.95, 95% C.I.: 0.90; 0.99). A significantly
greater number of elective operations (ORZ 3.27, 95%
C.I.: 2.14; 5.00), and significantly fewer emergency opera-
tions were also noticed (ORZ 0.48, 95% C.I.: 0.28; 0.83,
Fig. 2). Overall, there were significantly more operations
in the invited group compared to the controls (ORZ 1.75,
95% C.I.: 1.54; 1.99).Discussion
A meta-analysis should only be performed, if it includes
new data. Recently, a Cochrane review15 was published,
but it did not include data published after 2004e5, thus
missing important data from three of the four randomised
trials. In addition, it did not exclude unspecified aortic rup-
tures, which tends to underestimate the benefit in the MASS
trial. The results of this updated meta-analysis appear to
identify evidence of significant benefit in men. Pooled
data from the trials showed a significant mid-term reduc-
tion in AAA related and overall mortality after 3e5 years,
which were sustained in the long-term analysis. Also a sig-
nificant increase in rates of elective surgery of asymptom-
atic AAA resulting from screening was noticed, together
with a significant decrease in rates of emergency surgery.
However, there are some uncertainties in this review.
Odds ratios are not the most suitable and precise test to
use. Cox proportional hazards ratio analysis would be more
appropriate, but would require access to a merged data-
base containing raw data from all studies. Significant
heterogeneity was seen in the mid-term analysis. Although
overall mortality tended to decrease in all studies, only the
Western Australia study showed a significant decrease in
all-cause mortality, and the pooled results were not
significant using a random effect model. The updated
long-term results from the Western Australian study to-
gether with the other trials long term results show that
screening for AAA significantly decreases overall mortality.
Heterogeneity was noticed for elective surgery. There are
obvious explanations for this, including differences in the
prevalence of AAAs and indications for surgery. Heteroge-
neity was also noticed in the long term results of AAA-
related mortality. This may be due to the observed
differences between the British studies and the Viborg
Study. The British studies included aortic rupture at un-
specified sites. If these cases were removed from the
analysis, the OR in the MASS trial falls from 0.58 to 0.44
compared to 0.23 (95% C.I.: 0.11; 0.47) in the Viborg Study.
Although not a necessarily a significant factor, AAA-related
deaths may have been over-estimated in the screen group
of MASS as cause of death simply relied on the death
certificate, while the two other trials had independent
reviewers classify the cause of death in cases suspected to
be due to AAA. This may result in bias against screening for
AAA. Those with a known (screen-detected) AAA with
coexisting ischemic heart disease dying suddenly, are
more likely to have the cause of death attributed to AAA,
than a patient without an AAA. Finally heterogeneity wasnoticed for emergency operations. In the Chichester and
the Western Australian studies there was no reduction in
emergency operations in screened subjects, in contrast to
findings in the MASS and Viborg Studies. This may be a due
to younger populations in the MASS and Viborg Study.
In conclusion, screening for AAA reduces AAA-related
deaths and overall mortality, however, local differences in
health care settings could influence the local cost effec-
tiveness of screening.References
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